With the increasing demand for energy worldwide, researchers from different fields have been striving to improve the sustainability and proper utilization of energy resources. Passive radiative cooling, as a natural energy transport method, can achieve cooling without additional external energy input. This review provides a comprehensive examination of passive radiative cooling, including its fundamental theories and latest development. A particular emphasis is placed on the diverse range of fields where passive radiative cooling has been applied, notably including but not limited to construction and architecture. The current state of applications, potential challenges that may arise with wider adaption and promising research directions for each field are thoroughly discussed. This review underscores the universal applicability and feasibility of passive radiative cooling and contributes to its future development by identifying promising areas for further exploration.

Current methodologies for developing patient-derived xenografts (PDX) in humanized mice in preclinical trials to test response to immune-based therapies are limited by graft versus host disease. Here we compared two approaches for establishing PDX tumors in humanized mice: 1) PDX are first established in immune-deficient mice; 2) PDX are initially established in humanized mice, before transplanting established PDX’s to a larger cohort of humanized mice for preclinical trials. With the first approach, there was rapid wasting of PDX-bearing humanized mice with high levels of activated T cells in the circulation and organs, indicating immune-mediated toxicity. In contrast, with the second approach, toxicity was less of an issue and long-term human melanoma tumor growth and maintenance of human chimerism was achieved. Pre-clinical trials from the second approach revealed that rigosertib, but not anti-PD-1, increased CD8/CD4 T cell ratios in spleen and blood and inhibited PDX tumor growth. Resistance to anti-PD-1 was associated with limited infiltration of CD8+ T cell into the tumor. Our findings suggest that it is essential to carefully manage immune editing by first establishing PDX tumors in the presence of human immune cells before expanding PDX tumors into a larger cohort of humanized mice to evaluate therapy response.